• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Market characteristics
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product
o Desmopressin – Market size and forecast 2019-2024
o Replacement therapy – Market size and forecast 2019-2024
o Others – Market size and forecast 2019-2024
o Market opportunity by Product
• Customer Landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o APAC – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Apotex Inc.
o Baxter International Inc.
o Bio Products Laboratory Ltd.
o CSL Ltd.
o Ferring Pharmaceuticals AS
o Glenmark Pharmaceuticals Ltd.
o Grifols SA
o Octapharma AG
o Pfizer Inc.
o Takeda Pharmaceutical Co. Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2019 – 2024 ($ million)
• 13: Global market: Year-over-year growth 2019 – 2024 (%)
• 14: Five forces analysis 2019 & 2024
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2019
• 21: Product – Market share 2019-2024 (%)
• 22: Comparison by Product
• 23: Desmopressin – Market size and forecast 2019-2024 ($ million)
• 24: Desmopressin – Year-over-year growth 2019-2024 (%)
• 25: Replacement therapy – Market size and forecast 2019-2024 ($ million)
• 26: Replacement therapy – Year-over-year growth 2019-2024 (%)
• 27: Others – Market size and forecast 2019-2024 ($ million)
• 28: Others – Year-over-year growth 2019-2024 (%)
• 29: Market opportunity by Product
• 30: Customer landscape
• 31: Market share by geography 2019-2024 (%)
• 32: Geographic comparison
• 33: North America – Market size and forecast 2019-2024 ($ million)
• 34: North America – Year-over-year growth 2019-2024 (%)
• 35: Europe – Market size and forecast 2019-2024 ($ million)
• 36: Europe – Year-over-year growth 2019-2024 (%)
• 37: APAC – Market size and forecast 2019-2024 ($ million)
• 38: APAC – Year-over-year growth 2019-2024 (%)
• 39: ROW – Market size and forecast 2019-2024 ($ million)
• 40: ROW – Year-over-year growth 2019-2024 (%)
• 41: Key leading countries
• 42: Market opportunity by geography ($ million)
• 43: North America – Market size and forecast 2019-2024 ($ million)
• 44: North America – Year-over-year growth 2019-2024 (%)
• 45: Europe – Market size and forecast 2019-2024 ($ million)
• 46: Europe – Year-over-year growth 2019-2024 (%)
• 47: APAC – Market size and forecast 2019-2024 ($ million)
• 48: APAC – Year-over-year growth 2019-2024 (%)
• 49: ROW – Market size and forecast 2019-2024 ($ million)
• 50: ROW – Year-over-year growth 2019-2024 (%)
• 51: Impact of drivers and challenges
• 52: Vendor landscape
• 53: Landscape disruption
• 54: Industry risks
• 55: Vendors covered
• 56: Market positioning of vendors
• 57: Apotex Inc. – Overview
• 58: Apotex Inc. – Product and service
• 59: Apotex Inc. – Key offerings
• 60: Apotex Inc. – Key customers
• 61: Apotex Inc. – Segment focus
• 62: Baxter International Inc. – Overview
• 63: Baxter International Inc. – Business segments
• 64: Baxter International Inc. – Key offerings
• 65: Baxter International Inc. – Key customers
• 66: Baxter International Inc. – Segment focus
• 67: Bio Products Laboratory Ltd. – Overview
• 68: Bio Products Laboratory Ltd. – Product and service
• 69: Bio Products Laboratory Ltd. – Key offerings
• 70: Bio Products Laboratory Ltd. – Key customers
• 71: Bio Products Laboratory Ltd. – Segment focus
• 72: CSL Ltd. – Overview
• 73: CSL Ltd. – Business segments
• 74: CSL Ltd. – Key offerings
• 75: CSL Ltd. – Key customers
• 76: CSL Ltd. – Segment focus
• 77: Ferring Pharmaceuticals AS – Overview
• 78: Ferring Pharmaceuticals AS – Product and service
• 79: Ferring Pharmaceuticals AS – Key offerings
• 80: Ferring Pharmaceuticals AS – Key customers
• 81: Ferring Pharmaceuticals AS – Segment focus
• 82: Glenmark Pharmaceuticals Ltd. – Overview
• 83: Glenmark Pharmaceuticals Ltd. – Product and service
• 84: Glenmark Pharmaceuticals Ltd. – Key offerings
• 85: Glenmark Pharmaceuticals Ltd. – Key customers
• 86: Glenmark Pharmaceuticals Ltd. – Segment focus
• 87: Grifols SA – Overview
• 88: Grifols SA – Business segments
• 89: Grifols SA – Key offerings
• 90: Grifols SA – Key customers
• 91: Grifols SA – Segment focus
• 92: Octapharma AG – Overview
• 93: Octapharma AG – Product and service
• 94: Octapharma AG – Key offerings
• 95: Octapharma AG – Key customers
• 96: Octapharma AG – Segment focus
• 97: Pfizer Inc. – Overview
• 98: Pfizer Inc. – Business segments
• 99: Pfizer Inc. – Key offerings
• 100: Pfizer Inc. – Key customers
• 101: Pfizer Inc. – Segment focus
• 102: Takeda Pharmaceutical Co. Ltd. – Overview
• 103: Takeda Pharmaceutical Co. Ltd. – Product and service
• 104: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 105: Takeda Pharmaceutical Co. Ltd. – Key customers
• 106: Takeda Pharmaceutical Co. Ltd. – Segment focus
• 107: Currency conversion rates for US$
• 108: Research Methodology
• 109: Validation techniques employed for market sizing
• 110: Information sources
• 111: List of abbreviations
【掲載企業】
Apotex Inc., Baxter International Inc., Bio Products Laboratory Ltd., CSL Ltd., Ferring Pharmaceuticals AS, Glenmark Pharmaceuticals Ltd., Grifols SA, Octapharma AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd.
【免責事項】
https://www.marketreport.jp/reports-disclaimer